journal article·2024-02Open access

Comparison of Engineered Liver 3D Models and the Role of Oxygenation for Patient‐Derived Tumor Cells and Immortalized Cell Lines Cocultured with Tumor Stroma in the Detection of Hepatotoxins

Mona Mansouri, Astha Lamichhane, Dola Das, Federico Aucejo, Hossein Tavana, Nic D. Leipzig

Advanced Biology· Volume 8· Issue 2

Abstract

Abstract In metabolically active tumors, responses of cells to drugs are heavily influenced by oxygen availability via the surrounding vasculature alongside the extracellular matrix signaling. The objective of this study is to investigate hepatotoxicity by replicating critical features of hepatocellular carcinoma (HCC). This includes replicating 3D structures, metabolic activities, and tumor‐specific markers. The internal environment of spheroids comprised of cancerous human patient‐derived hepatocytes using microparticles is modulated to enhance the oxygenation state and recreate cell‐extracellular matrix interactions. Furthermore, the role of hepatic stellate cells in maintaining hepatocyte survival and function is explored and hepatocytes from two cellular sources (immortalized and patient‐derived) to create four formulations with and without microparticles are utilized. To investigate drug‐induced changes in metabolism and apoptosis in liver cells, coculture spheroids with and without microparticles are exposed to three hepatotoxic drugs. The use of microparticles increases levels of apoptotic markers in both liver models under drug treatments. This coincides with reduced levels of anti‐apoptotic proteins and increased levels of pro‐apoptotic proteins. Moreover, cells from different origins undergo apoptosis through distinct apoptotic pathways in response to identical drugs. This 3D microphysiological system offers a viable tool for liver cancer research to investigate mechanisms of apoptosis under different microenvironmental conditions.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Liver physiology and pathology · 3D Printing in Biomedical Research · Pancreatic function and diabetes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical, Biomolecular, and Corrosion Engineering The University of Akron Akron OH 44325 USA

Department of Biomedical Engineering The University of Akron Akron OH 44325 USA

Department of Biomedical Engineering Lerner Research Institute Cleveland Clinic Cleveland OH 44106 USA

Lerner College of Medicine Cleveland Clinic Cleveland OH 44195 USA

Funding

National Institute of Arthritis and Musculoskeletal and Skin Diseases · National Cancer Institute

References (74)

Show source-provided references
1. 10.1080/03602532.2022.203968810.1080/03602532.2022.2039688 ↗
2. 10.1016/j.engreg.2022.07.00410.1016/j.engreg.2022.07.004 ↗
3. 10.1002/biot.20160029510.1002/biot.201600295 ↗
4. Wang G. · Cell Death Dis. · 2020 · 11
5. 10.1039/C5RA04153H10.1039/C5RA04153H ↗
6. 10.1016/j.jcis.2020.09.08010.1016/j.jcis.2020.09.080 ↗
7. 10.1016/j.addr.2017.05.00710.1016/j.addr.2017.05.007 ↗
8. 10.1016/j.trecan.2020.10.00910.1016/j.trecan.2020.10.009 ↗
9. 10.1158/1541-7786.MCR-21-031710.1158/1541-7786.MCR-21-0317 ↗
10. 10.1002/jcp.2866510.1002/jcp.28665 ↗
11. 10.1021/acsami.1c1996210.1021/acsami.1c19962 ↗
12. 10.1039/C7IB00027H10.1039/C7IB00027H ↗
13. 10.3390/ijms2007162910.3390/ijms20071629 ↗
14. 10.3390/ijms2110345110.3390/ijms21103451 ↗
15. 10.3390/cancers1319493610.3390/cancers13194936 ↗
16. 10.1002/smll.20150293210.1002/smll.201502932 ↗
17. 10.1016/j.smaim.2022.12.00210.1016/j.smaim.2022.12.002 ↗
18. 10.3390/biology1005040810.3390/biology10050408 ↗
19. 10.1152/physrev.00013.200710.1152/physrev.00013.2007 ↗
20. 10.1002/bit.2845610.1002/bit.28456 ↗
21. 10.1016/j.tiv.2018.12.01410.1016/j.tiv.2018.12.014 ↗
22. 10.1126/sciadv.aas899810.1126/sciadv.aas8998 ↗
23. 10.1016/j.biomaterials.2010.07.06410.1016/j.biomaterials.2010.07.064 ↗
24. 10.1097/01.mpa.0000250129.64650.f610.1097/01.mpa.0000250129.64650.f6 ↗
25. 10.1038/nrc254010.1038/nrc2540 ↗
26. Smyrek I. · Biol. Open · 2019 · 8 · 7051
27. 10.1371/journal.pone.020337110.1371/journal.pone.0203371 ↗
28. 10.1016/j.biomaterials.2015.11.03110.1016/j.biomaterials.2015.11.031 ↗
29. 10.1038/s41598-017-10828-710.1038/s41598-017-10828-7 ↗
30. 10.1038/s41598-021-86016-510.1038/s41598-021-86016-5 ↗
31. 10.1093/toxsci/kfi05210.1093/toxsci/kfi052 ↗
32. 10.1089/ten.tec.2008.035210.1089/ten.tec.2008.0352 ↗
33. 10.1007/s42242-020-00121-410.1007/s42242-020-00121-4 ↗
34. 10.1089/adt.2018.89510.1089/adt.2018.895 ↗
35. 10.3350/cmh.2021.018810.3350/cmh.2021.0188 ↗
36. 10.3390/ijms22231313510.3390/ijms222313135 ↗
37. 10.1016/j.bej.2006.12.01010.1016/j.bej.2006.12.010 ↗
38. 10.1016/j.tranon.2018.11.00910.1016/j.tranon.2018.11.009 ↗
39. 10.2174/138920004348905410.2174/1389200043489054 ↗
40. 10.1021/acs.molpharmaceut.1c0046210.1021/acs.molpharmaceut.1c00462 ↗
41. 10.1124/dmd.118.08052310.1124/dmd.118.080523 ↗
42. 10.1016/j.toxlet.2020.05.00610.1016/j.toxlet.2020.05.006 ↗
43. 10.3727/105221620X1586872838160810.3727/105221620X15868728381608 ↗
44. 10.1124/dmd.30.5.60810.1124/dmd.30.5.608 ↗
45. 10.1002/hep.3199910.1002/hep.31999 ↗
46. 10.1006/abbi.2001.267710.1006/abbi.2001.2677 ↗
47. 10.3389/fonc.2021.66213510.3389/fonc.2021.662135 ↗
48. 10.1002/adhm.20160064410.1002/adhm.201600644 ↗
49. 10.1016/j.biopha.2009.06.00710.1016/j.biopha.2009.06.007 ↗
50. Shaaban S. · Oncol. Rev. · 2014 · 8 · 246
51. 10.1111/j.1742-7843.2004.pto940504.x10.1111/j.1742-7843.2004.pto940504.x ↗
52. 10.1021/acs.molpharmaceut.6b0052710.1021/acs.molpharmaceut.6b00527 ↗
53. 10.1016/j.biomaterials.2012.08.04010.1016/j.biomaterials.2012.08.040 ↗
54. 10.1016/j.trecan.2018.02.00510.1016/j.trecan.2018.02.005 ↗
55. 10.7150/ntno.3593510.7150/ntno.35935 ↗
56. 10.3390/ijms2017420310.3390/ijms20174203 ↗
57. 10.1093/toxsci/kfq20810.1093/toxsci/kfq208 ↗
58. 10.1002/ijc.2114410.1002/ijc.21144 ↗
59. 10.3389/fcell.2019.0007210.3389/fcell.2019.00072 ↗
60. 10.1016/j.bcp.2008.07.03110.1016/j.bcp.2008.07.031 ↗
61. 10.1089/ars.2012.490510.1089/ars.2012.4905 ↗
62. 10.1038/s41580-018-0089-810.1038/s41580-018-0089-8 ↗
63. 10.1089/biores.2016.000110.1089/biores.2016.0001 ↗
64. 10.1083/jcb.151.3.48310.1083/jcb.151.3.483 ↗
65. 10.7150/jca.3038110.7150/jca.30381 ↗
66. 10.1128/MCB.24.15.6592-6607.200410.1128/MCB.24.15.6592-6607.2004 ↗
67. 10.3390/mi903009410.3390/mi9030094 ↗
68. 10.1002/hep.2476010.1002/hep.24760 ↗
69. 10.1016/j.actbio.2012.10.03410.1016/j.actbio.2012.10.034 ↗
70. 10.1007/s10439-013-0925-010.1007/s10439-013-0925-0 ↗
71. Pascale F. · Anticancer Res. · 2015 · 35 · 6497
72. 10.3390/nu1424539410.3390/nu14245394 ↗
73. 10.1016/j.biomaterials.2010.09.06410.1016/j.biomaterials.2010.09.064 ↗
74. 10.1248/bpb.b17-0091310.1248/bpb.b17-00913 ↗